Modified DEP therapy for hemophagocytic lymphohistiocytosis (HLH)
Part of Blood & lymphatic clinical trials.
This trial tests a modified combination of drugs (liposomal doxorubicin, etoposide, and ruxolitinib, with or without a PD-1 inhibitor) for people with HLH. The goal is to see if it helps control the overactive immune response better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HLH based on the HLH-2004 criteria.
- You are between 1 and 70 years old.
- Your liver and kidney function are within safe limits (bilirubin ≤10x upper normal, creatinine ≤1.5x normal, and fibrinogen can be corrected to ≥0.6 g/L).
- You do not have active HIV, hepatitis B or C (or if you do, the virus is well-controlled).
- You are not pregnant or breastfeeding, and you agree to use contraception during and after the study (women: 6 months, men: 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests two drugs, emapalumab and ruxolitinib, in people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. The goal is to find the safest and most effective doses of these medications.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Hear when a new Hemophagocytic Lymphohistiocytoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.